Cici Sarl Pharmaceutical Import Profile — Senegal (DGFT 2022–2026)

Name: Cici Sarl Pharmaceutical Import Records from India — 4 Products, $4.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cici Sarl — Pharmaceutical Importer Profile (2026) | 4 Products, $4.6M Trade | TransData Nexus

Cici Sarl

Pharmaceutical Importer · Senegal · Analgesics & Antipyretics Focus · $4.6M Total Trade · DGFT Verified

Cici Sarl is a pharmaceutical importer based in Senegal with a total trade value of $4.6M across 4 products in 4 therapeutic categories. Based on 187 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cici Sarl sources from 29 verified Indian suppliers, with Twin Impex accounting for 28.9% of imports.

Cici Sarl — Import Portfolio & Supplier Network

Cici Sarl import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cici Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Twin Impex	$4.5M	372	28.9%
Unilink Pharma Private Limited	$1.7M	49	11.1%
Sunlovis Pharmaceuticals Llp	$1.6M	70

What Formulations Does Cici Sarl Import?

Formulation	Value	Ships
Sudrek tablets( paracetamol BP 325MG +	$750.0K	15
Harmless medicines paracetamol b.p.325	$436.1K	41
Harmless medicines for human	$418.8K	11
Pharmaceutical products, paracetamol	$359.8K	17
Harmless medicines for human	$340.8K	28
Harmless medicines paracetamol b.p.500	$265.7K	9
Harmless medicines diclofenac sodium	$246.4K	20
Mikagripe tablets(paracetamol BP 325 MG	$229.9K	8
Amoxicillin capsules BP, batch	$205.8K	11
Ampicillin capsules BP, batch	$189.4K	4
Harmless medicines paracetamol b.p.500 MG.Each uncoated TAB contains paracetamol 96	$160.3K	6
Harmless medicines loperamide hcl	$143.5K	11
Harmless medicines ciprofloxacin	$142.4K	4
Prematin tablets (cyproheptadine	$132.6K	5
Ladymax tablets( paracetamol BP 325MG	$125.5K	3

Cici Sarl imports 534 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paracetamol	Analgesics & Antipyretics	$3.3M	111	0.9%	11
2	Caffeine	Respiratory & OTC	$1.1M	59	1.1%	13
3	Acetylsalicylic	Combination Drugs	$69.7K	10	1.6%	10
4	Niacin	Lipid & Metabolism	$44.4K	7	1.2%	13

Cici Sarl imports 4 pharmaceutical products across 4 categories into Senegal totaling $4.6M.

Cici Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cici Sarl is a pharmaceutical importer based in Senegal, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a diverse range of pharmaceutical products to meet the healthcare needs within Senegal. Headquartered in the Zone Industrielle area, facing Sonatam Bamako Mali, Senegal, Cici Sarl plays a pivotal role in the distribution of pharmaceutical products across the country.

The company's import portfolio is extensive, encompassing 534 unique formulations across four therapeutic categories. This diversity underscores Cici Sarl's commitment to providing a comprehensive range of pharmaceutical solutions to the Senegalese market. The company's strategic sourcing from India aligns with Senegal's growing demand for quality pharmaceutical products, positioning Cici Sarl as a key player in the nation's pharmaceutical supply chain.

2Distribution Network

Cici Sarl's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Senegal. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's significant import volume indicates a well-established infrastructure capable of handling substantial shipments. The geographic coverage extends across Senegal, facilitating widespread access to essential medications. The company's operations are primarily centered in the Zone Industrielle area, suggesting a focus on optimizing logistics and distribution within this region.

3Industry Role

In Senegal's pharmaceutical supply chain, Cici Sarl functions as a primary wholesaler and importer. By sourcing a wide array of pharmaceutical formulations from India, the company serves as a critical intermediary between international manufacturers and the local market. This role is essential in ensuring the availability of diverse pharmaceutical products to meet the healthcare needs of the Senegalese population. Cici Sarl's operations contribute significantly to the efficiency and effectiveness of the pharmaceutical distribution network within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cici Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cici Sarl's sourcing strategy exhibits a high degree of concentration, with a substantial majority of its pharmaceutical imports originating from India. The company's top five products—Paracetamol, Caffeine, Acetylsalicylic Acid, Niacin, and Omeprazole—are sourced exclusively from Indian suppliers. This concentrated sourcing approach suggests a strategic decision to leverage India's established pharmaceutical manufacturing capabilities and cost advantages. However, such dependency on a single source country may pose risks related to supply chain disruptions, currency fluctuations, and geopolitical factors. The stability of Cici Sarl's relationships with its Indian suppliers, as evidenced by the consistent import volumes and long-term partnerships, indicates a robust and reliable supply chain. Nonetheless, the company may benefit from exploring diversification strategies to mitigate potential risks associated with sourcing concentration.

2Supply Chain Resilience

Cici Sarl's supply chain resilience is closely tied to its exclusive reliance on Indian suppliers for pharmaceutical imports. The company's top suppliers, including TWIN IMPEX, UNILINK PHARMA PRIVATE LIMITED, and SUNLOVIS PHARMACEUTICALS LLP, have demonstrated consistent performance, contributing to the company's ability to meet the pharmaceutical demands of the Senegalese market. However, the lack of publicly available information regarding backup suppliers and the diversity of formulations imported suggests potential vulnerabilities in the supply chain. To enhance resilience, Cici Sarl might consider establishing relationships with additional suppliers from other countries and diversifying its product portfolio. This approach could provide greater flexibility and security in the face of unforeseen disruptions.

Importing Pharmaceuticals into Senegal — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Senegal

1Regulatory Authority & Framework

In Senegal, the regulation of pharmaceutical products is overseen by the Directorate of Pharmacy and Medicine (Direction de la Pharmacie et du Médicament), which operates under the Ministry of Health and Social Action. This regulatory body is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the country. Key legislation governing pharmaceutical imports includes the Law No. 2009-09 of 4 May 2009, which establishes the framework for the regulation of pharmaceutical products, and the Decree No. 2010-1056 of 28 September 2010, which outlines the procedures for the importation of pharmaceutical products. These regulations are designed to protect public health by ensuring that all pharmaceutical products meet established standards before entering the Senegalese market.

2Import Licensing & GMP

Importers of pharmaceutical products into Senegal, such as Cici Sarl, are required to obtain an import authorization from the Directorate of Pharmacy and Medicine. This authorization ensures that imported products comply with Senegalese regulations and standards. Additionally, pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) as recognized by the World Health Organization (WHO) or the European Union (EU). Senegal accepts GMP certificates from these recognized bodies, facilitating the importation of quality pharmaceutical products. Wholesalers and distributors, including Cici Sarl, must also comply with Good Distribution Practices (GDP) to ensure the integrity and quality of pharmaceutical products throughout the supply chain.

Cici Sarl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cici Sarl's focus on importing analgesics and antipyretics, respiratory and over-the-counter (OTC) medications, and combination drugs aligns with the prevalent health concerns in Senegal. The high import value of Paracetamol and Caffeine indicates a significant demand for pain relief and stimulant medications. The inclusion of respiratory and OTC products suggests a strategy to address common ailments and provide accessible healthcare solutions. This product mix reflects Cici Sarl's responsiveness to the healthcare needs of the Senegalese population.

2Sourcing Profile

Cici Sarl's sourcing strategy is centered on procuring generic pharmaceutical formulations from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's preference for finished pharmaceutical products over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market solutions. India's compliance with international GMP standards and the availability of a diverse range of formulations make it a strategic partner for Cici Sarl in meeting the pharmaceutical needs of the Senegalese market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Cici Sarl

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Cici Sarl, given the company's established distribution network and focus on sourcing from India. Potential gaps in Cici Sarl's current sourcing include the need for diversification in product formulations and the exploration of alternative suppliers to enhance supply chain resilience. Indian exporters can leverage these opportunities by offering a diverse range of high-quality pharmaceutical products that align with Cici Sarl's import strategy.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Cici Sarl and the Senegalese market must ensure compliance with international GMP standards recognized by WHO or the EU. Products must meet Senegalese quality control measures, including batch testing and stability assessments. Labeling must be in French, adhering to Senegalese regulations. Additionally, exporters should be prepared to provide necessary documentation, such as certificates of origin and commercial invoices, to facilitate the import process.

3How to Approach

Frequently Asked Questions — Cici Sarl

What products does Cici Sarl import from India?

Cici Sarl imports 4 pharmaceutical products across 4 categories. Top imports: Paracetamol ($3.3M), Caffeine ($1.1M), Acetylsalicylic ($69.7K), Niacin ($44.4K).

Who supplies pharmaceuticals to Cici Sarl from India?

Cici Sarl sources from 29 verified Indian suppliers. The primary supplier is Twin Impex (28.9% of imports, $4.5M).

What is Cici Sarl's total pharmaceutical import value?

Cici Sarl's total pharmaceutical import value from India is $4.6M, based on 187 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cici Sarl focus on?

Cici Sarl imports across 4 categories. The largest: Analgesics & Antipyretics (72.7%), Respiratory & OTC (24.8%), Combination Drugs (1.5%).

Get Full Cici Sarl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.